Meeting
2021 ASCO Annual Meeting
Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI).
Presenter
Joe Grimes
Columbia University Vagelos College of Physicians and Surgeons
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9535)
DOI
10.1200/JCO.2021.39.15_suppl.9535
Abstract #
9535
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors.
Speaker: Yusra F. Shao, MD
Videos & Slides
2024 ASCO Breakthrough
Prognostic value of immuno-nutritional status in patients with cancer treated by immune checkpoint inhibitors.
Speaker: Ming-Chun Kuo
Videos & Slides
2024 ASCO Breakthrough
Efficacy of combination of immune checkpoint inhibitors, chemotherapy, and targeted therapy in advanced/refractory cancer.
Speaker: Khaled W. Jabboury, MD
Videos & Slides
2024 ASCO Annual Meeting
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).
Speaker: Anthony B. El-Khoueiry, MD